Table 3.

Treatment and outcome characteristics

Characteristic	All patients (N = 71)	RT only (n = 36)	Combined therapy (n = 29)	RT-only vs combined therapy, P	Systemic therapy (n = 6)
Treatment
Systemic only	6 (9)
Radiation only	36 (51)
Combined	29 (41)
Treatment era
Before 2000	8 (11)	6 (17)	2 (7)	.444	0
2000–2010	30 (42)	14 (39)	11 (38)		5 (83)
2011–2017	33 (47)	16 (44)	16 (55)		1 (17)
Systemic therapy (n = 35)
R-ABVD	5 (7)		4 (14)		1 (17)
R-CHOP	22 (31)		19 (66)		3 (50)
Rituximab	5 (7)		3 (10)		2 (33)
Other	3 (4)		3 (10)
RT (n = 65)
EFRT	12 (17)	9 (25)	3 (10)	.088
IFRT	20 (28)	13 (36)	7 (24)
ISRT	33 (47)	14 (39)	19 (66)
RT (n = 65)
3-Dimensional	39 (60)	27 (75)	12 (41)	.010
Intensity-modulated RT	26 (40)	9 (25)	17 (59)
Radiation dose (n = 65)
Median (range), Gy	30.6 (21.6-40.0)	36 (30-40)	30.6 (21.6-40)
>30.6 Gy	32 (49)	26 (72)	6 (21)	<.001
≤30.6 Gy	33 (51)	10 (28)	23 (79)
Death
Yes	6 (8)	3 (8)	2 (7)		1 (17)
No	65 (92)	33 (92)	27 (93)		5 (83)
Relapse or progression
Yes	15 (21)	8 (22)	5 (17)		2 (33)
No	56 (79)	28 (78)	24 (83)		4 (67)
Local relapse
Yes	2 (3)	0	0		2 (33)
No	69 (97)	36 (100)	29 (100)		4 (67)
Distant relapse
Yes	13 (18)	8 (22)	5 (17)		0
No	58 (82)	28 (78)	24 (83)		6 (100)
Transformation
Yes	2 (3)	1 (3)	1 (3)	.876	0
No	69 (97)	35 (97)	28 (97)
Second malignancy
Yes	8 (11)	3 (8)	5 (17)	.277	0
No	63 (89)	33 (92)	24 (83)		6 (100)
Median follow-up (95% CI), y*	6.1 (5.0-7.2)	6.1 (3.3-8.9)	4.4 (0.42–8.4)	.174	7.5 (4.0-11.0)

Unless otherwise noted, all data are n (%).

^*P value for comparison of all 3 groups is .341.